The World Health Organization drew a line at age 10. On October 7, it released its first global guidelines on treating obesity in children and adolescents, and under that line, drugs, weight-loss surgery and devices are off the table. Above it, they are allowed, but only after a supervised lifestyle programme has failed to deliver. For a medical field that has been rushing toward GLP-1 prescriptions, it is a deliberate brake.

Why WHO wrote it now

The numbers explain the urgency. In 2024, 170 million children and adolescents aged 5 to 19 were living with obesity, WHO said, including 70 million aged 5 to 9 and 100 million aged 10 to 19. Prevalence in this age group has quadrupled since 1990, from 2 percent to 8 percent. Until this week, WHO had issued guidance on adult obesity, including conditional approval for GLP-1 medicines in 2025, but nothing equivalent for children, according to Health Policy Watch.

WHO describes obesity as a chronic, relapsing disease that can be managed with effective care. That framing matters. It moves the discussion away from willpower and toward treatment, and it explains why the agency wanted a single global standard rather than a patchwork of national advice.

What the guidelines actually say

For every child and adolescent with obesity, WHO strongly recommends structured diet, physical activity and behaviour-change programmes, delivered individually or as part of a multimodal programme. Digital tools such as apps and active video games earn a conditional recommendation, and only with parent or caregiver supervision, Health Policy Watch reported.

For children aged 0 to 9, WHO does not recommend medicines, bariatric surgery or weight-loss devices. For adolescents aged 10 to 19, approved medicines may be considered only when a supervised multimodal lifestyle programme has not achieved the desired results. Bariatric surgery may be considered under strict conditions for adolescents with severe obesity.

WHO's Dr. Luz María De Regil, who directs its Department of Nutrition and Food Safety, said the foundation of care is not medicine or surgery but access to comprehensive support for healthy eating, physical activity and sustainable behaviour change.

The guidelines also ask health workers to address mental health alongside weight. Anxiety, depression, low self-esteem and bullying can drive both eating patterns and social withdrawal, WHO noted, so clinicians are told to treat the two together. And the goal is not simply a lower number on the scale. WHO says care should aim at health, function and wellbeing, with long-term follow-up.

The evidence gap behind the caution

Why the brake on drugs? A news report on the guidelines quoted their own assessment that evidence for medicines, including GLP-1s, metformin and sibutramine, is generally low quality, because follow-up has been short and the studies and participant numbers small. That is a significant admission. A strong recommendation requires strong evidence, and WHO's drug recommendation is conditional for exactly that reason.

Real-world prescribing has moved faster than the evidence. A study published in the journal Pediatrics in September found that GLP-1 prescriptions for children aged 8 to 11 rose sharply between 2019 and 2026, Health Policy Watch reported. WHO's cutoff of 10 for even considering drugs sits inside that group.

National guidance already differs. According to the same news coverage, Canadian recommendations suggest GLP-1s only from age 12 and do not require lifestyle measures to be tried first. WHO is stricter on sequence and slightly more permissive on age. Two serious bodies reading similar evidence landing in different places is consistent with how limited that evidence still is.

What the guidelines cannot fix

A treatment guideline governs what happens in a clinic, and WHO is explicit that this is not enough. Treatment alone cannot reverse the rise in obesity, the agency said, and it continues to call for policies that make healthy diets and physical activity more accessible and affordable, including regulatory and fiscal measures and action on education, urban planning, transport and social protection.

That is the quiet tension in the document. It tells doctors to start with lifestyle programmes, but a lifestyle programme only works if a family can afford healthy food, a child has somewhere safe to play and a health system has the staff to deliver structured support. Where that support is scarce, the risk is that the programme WHO says must come first becomes the hardest step to deliver.

The guidelines will be judged less by what they say about drugs than by whether governments fund what they put first. If they do not, the rule of lifestyle first will not stop prescribing. It will just make the lifestyle step a box that gets ticked.

---